Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Lancet Oncol 2022 Nov 15;[EPub Ahead of Print], S Siva, M Ali, RJM Correa, A Muacevic, L Ponsky, RJ Ellis, SS Lo, H Onishi, A Swaminath, M McLaughlin, SC Morgan, FL Cury, BS Teh, A Mahadevan, ID Kaplan, W Chu, W Grubb, R Hannan, M Staehler, A Warner, AV Louie
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.